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INTRODUCTION:
 1, 2, 3, 4) 
Various techniques have been employed to formulate oral 
drug delivery system that would enhance the dissolution 
profile and in turn, the absorption efficiency of water 
insoluble drug. Solid dispersion, drug micronisation, 
lyophilisation, microencapsulation, inclusion of the  drug 
solution or liquid drug into soft gelatin capsules are some 
of the methods that have been used to enhance dissolution 
characteristics of water insoluble drugs. Among them, 
lipospheres are amongst the promising particulate drug 
delivery systems for improving dissolution rate of water 
insoluble drugs that were initially reported as a particulate 
dispersion of solid spherical particles between 0.2-100μm 
in diameter consisting of solid hydrophobic fat core such 
as triglycerides or fatty acids derivatives, stabilized by 
monolayer of phospholipids. Lipospheres represent a new 
type of fat based encapsulation system developed for 
parenteral and topical delivery of bioactive compounds and 
have been utilized in the delivery of anti-inflammatory 
compounds, local anaesthetics; antibiotics, anticancer 
agents, insect repellent, vaccines, proteins and peptides. 
The lipospheres are distinct from microspheres of 
uniformly dispersed material in homogenous polymer 
since they consist of two layers, the inner solid particle that 
contains the entrapped drug with phospholipids outer 
layer. The combination of solid inner core with 
phospholipid exterior confers several advantages on the 
lipospheres as compared with conventional microspheres 
and microparticles, including high dispersibility in aqueous 
medium, and a release rate for the entrapped substance that 
is controlled by the phospholipid coating and the carrier. 
Further, the substance to be delivered does not have to be 
soluble in the vehicle since it can be dispersed in the solid 
carrier. Lipospheres have a lower risk of drug –excipient 
interactions due to the solid nature of vehicle. Moreover, 
the drug release rate can be manipulated by altering either 
or both the inner solid vehicle or the outer phospholipid 
layer. The ease of preparation as compared to liposomes 
that have inherent problem of stability adds an advantage 
over other lipid systems. Fenofibrate (FNO), a BCS class-
II drug is a third-generation fibric acid derivative 
employed clinically as a hypolipidemic agent to lessen the 
risk caused by atherosclerosis.  
MATERIALS AND METHODS 
Materials: 
Fenofibrate was procured as gift sample from Alembic 
Pharma Gujarat; India. Stearic acid , paraffin oil 80 and 
rest of the raw materials and solvents were purchased from 
were purchased from Himedia Lab Pvt. Ltd. and Loba 
Chemicals Pvt. Ltd. Mumbai India. 
Method 
Preformulation Studies: 
Organoleptic properties of Drug:
 5, 6, 7 
The drug FNO was analyzed visually for organoleptic 
properties, like colour, odour and appearance. 
Melting point determination 
A small amount (2-4mg) of sample was transferred into a 
small closed-end capillary tube and gently tapped on the 
bench top until the sample reached to the bottom of the 
tube avoiding the firm packing of the material in the end of 
the tube, and was placed vertically with closed end 
downward in the holes located in the top of the base of 
Digital Melting Point Apparatus. Speed of knob was 
adjusted to medium to avoid the formation of bubbles. The 
dial was adjusted to the appropriate temperature. The 
sample temperature was gradually raised simultaneously 
reaching the bath temperature. The melting point 
determination was carried out using the periscopic viewer 
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to help monitor the temperature at which the sample melts. 
The procedure was repeated thrice. 
Solubility profile: 
An accurately weighed 100mg of FNO was dissolved 
separately each in 10ml of distilled water and a mixture of 
phosphate buffer pH6.8 with 1% SLS in the ratio 9:1 and 
the solubility was observed visually. 
Saturation solubility study 
Saturation solubility of FNO  was determined following 
standard approach by stirring an excess amount of drug 
separately in distilled  water ,9:1 mixture   PBS pH 6.8and  
1%SLS in 100ml separate calibrated volumetric flasks at 
room temperature (25ºC) for 15 hours. The sample were 
taken manually and filtered through 0.45μm filters and the 
absorbance was determined by UV-visible 
spectrophotometer (UV/VIS) spectrophotometer (V-630, 
Jasco Corporation Tokyo, Japan), at 280 and 290nm 
respectively for both the solvent system. The procedure 
was repeated until the maximum concentration of the drug 
was achieved till the constant concentration in both the 
solvent. 
Calibration curve 
Phosphate buffer pH6.8 (PBSpH6.8): 
An accurately weighed (100mg) of FNO was dissolved in 
100 ml solution  containing 90ml PBS pH 6.8 and 10ml of 
1% SLS in 100ml calibrated volumetric flask. The 
dilutions of 2, 4, 6, 8, 10, 12, 14, 16, 18, 20g/ml were 
prepared. Absorbance of each solution was measured at 
290nm in triplicate by taking PBSpH6.8 and 1% SLS (9:1) 
as a reference standard. 
Fourier Transform Infrared Spectrophotometer 
(FTIR): 
The IR absorption spectra of FNO were recorded by 
potassium bromide dispersion technique. Dry sample of 
drugs and potassium bromide were mixed uniformly and 
filled into the die cavity of sample holder and an IR 
spectrum was recorded separately using FTIR 
spectrophotometer (JASCO– FT/IR- 4100) in the range 
500-4000. The resultant spectrum of the FNO was 
compared with reference spectrum of FNO respectively. 
Differential Scanning Calorimetry(DSC): 
The thermal behavior of FNO, were studied using 
Shimadzu D.S.C TA60 WS Thermal Analyzer. Accurately 
weighed samples of FNO (8.00mg), was run at the 
scanning rate of 15°C/min and 20˚C/min over a 
temperature range of 100°C to 300°C respectively. The 
system was calibrated with a high purity sample of Indium. 
Peak transitions and enthalpy of fusion were determined 
for the samples using TA 60 integration software 
Drug excipients compatibility study: 
The accurately weighed one gm FNO and excipients in the 
ratio of 1:1 were subjected to storage at room temperature 
and elevated temperature of 400C for one month in sealed 
amber colored twelve vials. Sampling was performed at a 
predetermined time intervals of 7, 14, 21 and 30days. The 
samples were analyzed for any interaction between drug 
and excipient by FTIR studies. 
Preparation of Liposphere by Melt Dispersion 
Technique:
 8
 
A mixture of paraffin oil and stearic acid was melted to 
obtain a one phase melt on thermostate hot plate (2 MLH, 
Remi Equipment Ltd.India). FNO was dispersed in the 
molten solution and the temperature of the resulting oil 
phase was maintained at 70°C. The surfactant solution 
comprising 1%( v/v) of Tween 80 in water was maintained 
at a temperature of 80°C under continuous stirring using 
propeller stirrer (RQ 121 D Remi Equipment Ltd.). The 
molten oily phase was emulsified in the aqueous surfactant 
solution maintained at 28000rpm on ultra turrax (IKA® 
T25). Hardening of the oily internal phase resulting in 
encapsulation of the drug was accomplished by pouring 
twice the emulsion volume of ice cold water maintained at 
4°C. The resulted lipospheres were separated by filtration, 
washed with ice cold water and dried at room temperature 
(24°C) for 24hours. 
EVALUATION OF LIPOSPHERES 
Bulk Characterization: 
Angle of Repose 
The angle of repose for the lipospheres of each batch was 
determined by the funnel method. Accurately weighed 
10gm of lipospheres were allowed to flow out of the 
funnel orifice fixed at a height of 2cm from the surface on 
a plane paper kept on the horizontal platform. The gradual 
addition of the lipospheres from the funnel mouth formed a 
pile of granules on the surface this was continued until the 
pile touches the stem tip of the funnel. A rough circle was 
drawn around the pile base and the radius of the powder 
cone was measured. Angle of repose was calculated by 
using the following formula: 
 =tan−1
h
r
  (1) 
Where, 
Ɵ = angle of repose  
h = height of the pile 
r = Average radius of the powder cone  
Bulk Density 
Accurately weighed 10gm of lipospheres were placed into 
a 50ml cylinder of the bulk densitometer (CL100). The 
volume occupied by the sample was recorded. The bulk 
density was calculated as following formula: 
Bulk Density = 
 Weight  of  Sample  in  gm
Volume  Occupied  by  Sample
  (2) 
Tapped Density 
Accurately weighed 10gm of lipospheres were poured 
gently through a glass funnel into a cylinder of bulk 
densitometer (CL100). The cylinder was tapped from  a 
height of 2 inches until a constant volume was obtained. 
Volume occupied by the sample after tapping were 
recorded and tapped density was calculated as follows by 
formula. 
Tapped Density = 
Weigh t of  Sample  in  gm
Volume  Occupied  by  Sample  after  tapping
    (3) 
Carr’s Index (CI) 
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One of the important measures that can be obtained from 
bulk and tapped density determinations is the percent 
compressibility or the Carr’s index, I, which is determined 
by the following formula 
Carr’s Index = 
Tapped  Density −Bulk  Density
Tapped  Density
  (4) 
% Yield
 
(%Y)( 9) 
Dried lipospheres were accurately weighed, and 
considering the total amount of drug and excipient used for 
preparing the feed solution, the % yield of liposphere was 
calculated using the following formula  
% Yield = 
Total  Weight  of  Liposphere
Total  Solid  Material  Amount  used  before  Emulsification  
× 100 (5) 
% Drug Entrapment (%DE)
9
 
Accurately weighed 100mg of Lipospheres were dissolved 
in 100ml of PBSpH6.8.The solution was kept overnight 
and was filtered through whatman filter 0.45µm. The drug 
concentration was determined by UV spectrometer at 
maximum wavelength of 290nm. The following equation 
was used to calculate % drug entrapment: 
%Drug Entrapment = 
 Calculated  Drug  Content
Therotical  Drug  Content
× 100            (6) 
Morphology 
10
 
The morphology of the optimized batch of lipospheres was 
investigated using Scanning Electron Microscopy (SEM). 
The samples were prepared by sprinkling the formulation 
on double-adhesive tape stuck to aluminum stub. The stub 
was placed in high-vacuum evaporator. The samples were 
then randomly scanned and photomicrographs were taken 
with a Scanning Electron Microscope (Joel JSM-630A). 
DSC  
The thermal behavior of the samples were determined with 
a DSC-823e, Mettler Toledo, cell using aluminum 
crucibles with about 2mg of the lipospheres, under 
dynamic N2 atmosphere (40ml min−1) at a heating rate of 
10 °C min−1 in the temperature range of 25 to 300°C. The 
DSC cell was calibrated with indium (mp 156.6°C; ΔH fuss 
=28.54 J g−1) and zinc (mp 419.6°C). 
In-vitro cumulative % drug release study 
11
 
The FNO release from the lipospheres was evaluated by 
using the US Pharmacopoeia Dissolution Apparatus-II 
Paddle (XVIII) in 900ml mixture of PBSpH6.8 with 1% 
SLS in 9:1 at 37°C ± 0.5 temperature. The rotational speed 
of dissolution apparatus was maintained at 100rpm. Each 
run was carried out in triplicates. Accurately weighed 
243mg of lipospheres were filled in a “0” size capsule to 
get the final weight of 475mg each of the capsules was 
transformed into dissolution media. The 5ml samples were 
withdrawn at predetermined time intervals with dissolution 
media replacement and were filtered through 0.45µm 
whatman filter paper. The drug content was determined 
spectrophotometrically at 290nm on Jasco-630 UV/ Vis-
spectrophotometer.  
Preparation of optimized batch Q1 
The optimized batch  Q1was formulated using the 
predicted values of the concentration of stearic acid and 
paraffin oil from the surface response graph of xi,x2 for 
reponses y1() , y2 () obtained from software design expert 
version 8. 
Evaluation of optimized batch Q1 
Saturation Solubility: 
Saturation solubility of  the optimized batch Q1was 
determined  by stirring excess amount of samples of  
lipospheres , physical mixture of drug, stearic acid and 
paraffin oil in the ratio of 1:1:0.2 in distilled water and 9:1 
mixture of PBS pH 6.8 with 1%SLS in 100ml separate 
calibrated volumetric flasks at room temperature (25ºC) 
for 15 hours. The samples were taken manually and 
filtered through 0.45μm filters and the absorbance was 
noted at 290nm UV-visible spectrophotometer (UV/VIS) 
spectrophotometer (V-630, Jasco Corporation Tokyo, 
Japan). The procedure was repeated until the maximum 
concentration of the drug was achieved till the constant 
concentration in both the solvent. 
In-vitro cumulative % drug release study 
11 
The FNO release optimized batch Q1 was evaluated by 
using the US Pharmacopoeia Dissolution Apparatus-II 
Paddle (XVIII) in 900ml mixture of PBSpH6.8 with 1% 
SLS in 9:1 at 37°C ± 0.5 temperature. The rotational speed 
of dissolution apparatus was maintained at 100rpm. Each 
run was carried out in triplicates. Accurately weighed 
243mg of lipospheres were filled in a “0” size capsule to 
get the final weight of 475mg each of the capsules was 
transformed  into dissolution media. The 5ml samples were 
withdrawn at predetermined time intervals with dissolution 
media replacement and were filtered through 0.45µm 
whatman filter paper. The drug content was determined 
spectrophotometrically at 290nm on Jasco-630 UV/ Vis-
spectrophotometer.  
In vivo study: 
The in vivo study was performed on normal healthy Wistar 
albino rats. The animal experiments were conducted in full 
compliance with local, national, ethical, and regulatory 
principles and local licensing regulations, per the spirit of 
Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC) International’s 
expectations for animal care and use/ethics committees. 
The approval (CPCSEA/IAEC02/02/2012) of the 
Institutional Animal Ethics Committee was obtained 
before starting the study.  
Animals 
Two groups of male Wistar albino rats weighing 150 to 
200g each (4 in each group) under fasting condition prior 
to experiment were used for the study.  
Induction of Hyperlipidemia 
9
 
Hypercholesterolemia was induced by adding 500mg/kg 
cholesterol powder, 250mg/kg of cholic acid and 10ml/kg 
of groundnut oil to the food. The animals were divided into 
control and experimental group. Two groups each of three 
rats each were fed on the following diet for 2 weeks. Blood 
samples were collected after 2 weeks and blood glucose 
levels were estimated. The suspensions of FNO 
lipospheres were administered orally at a dose equivalent 
to 800g/kg to respective group using stomach intubation. 
Blood samples were withdrawn at predetermined time 
intervals of 0, 1, 2, 4, 6.8, 10, 12 and 24hours by retro 
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orbital puncture. The blood glucose level of the control 
and test samples was determined using the glucose 
measuring instrument auto analyzer (IKA® T25) .The 
percentage reduction in the blood glucose level was plotted 
against time. 
 
RESULTS 
Organoleptic properties of drug:  
The FNO was checked visually for color, odor, appearance 
melting point and solubility. The results have been 
depicted in the Table I. 
 
 
Table I: Organoleptic properties of FNO 
Characterization Parameter 
Organoleptic Properties Melting Point Solubility 
Colour Odour Appearance 
FNO Red orange Characteristics Amorphous 79 to86°C Very slightly soluble 
 
The melting point of FNO, was determined by capillary 
method using Digital Melting Point apparatus was found 
to be 82°C. The value was comparable with the literature 
value of 69 TO 86°C.given in Table I. The melting point 
as obtained practically matched the literature value 
confirms the purity of the sample 
The solutions were checked visually for their clarity. The 
phosphate buffer water system (9:1) found to be turbid. 
Saturation solubility:   
Table II enlists the saturation solubility of FNO and 
physical mixture of FNO, stearic acid and paraffin oil in 
ratio 1:1.5:0.2.in different media.The solubility of FNO 
was improved when mixed with stearic acid and paraffin 
oil.  
Table II: Saturation solubility of FNO in different 
solvent 
Solvent FNO Physical mixture 
Water 98.54µg/ml 170.21µg/ml 
PBS 6.8 with 1% SLS 167.74µg/ml 261.94µg/ml 
 
Calibration Curve: 
Calibration curve of FNO was carried out in PBS pH6.8 
system (9:1) as shown in the Figure I. The Beer-
Lambert’s law was obeyed in PBS pH6.8 system in the 
range of 2 to 20µg/ml at wavelength 290nm. 
 
Figure I: Calibration curve in 6.8 pH phosphate buffer with 1%M SLS 
FTIR study of drug excipients: 
The FTIR of FNO was determined by using Jasco software 
as shown in the Figure II. The result has been presented in 
the Table III. The FT-IR finger prints of FNO 
demonstrated characteristic peak at 3211cm-1 due to 
monosubstituted benzene ring. The peak at 3439cm-1 
indicates the presence of phenol moiety. Characteristic 
peaks were obtained at 1796 and 1225cm
-1
 due to aromatic 
ester moieties and peak at 1625cm-1 indicate the presence 
of carboxylic group. Presence of CH2Cl group is indicated 
by peak at 1225cm-1.Thus the FT-IR spectra confirm the 
purity of the FNO. 
Table III: Interpretation of IR spectra 
Frequency (cm-1) Interpretation 
3039 Alkanes 
3211 Monosubsituted benzene ring 
3439 Phenols 
3514 1,4-Disustituted phenol 
1417 -CH3 group 
1625 Carboxylic group 
1796,1225 Aromatic  ester 
1225 -CH2Cl 
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Figure II: FTIR Spectra of Fenofibrate 
Differential Scanning Calorimetry( DSC): 
The DSC thermogram of FNO and stearic acid has been 
depicted in Figure III. The DSC of FNO exhibited broad 
endothermic peak at 82°C indicates melting point of FNO. 
Lack of sharp melting peak in the DSC of a FNO in the 
Figure III indicates that the FNO is present in an 
amorphous rather than crystalline form of FNO. The sharp 
endothermic peak at 68°C represent melting point of 
stearic acid. 
 
Figure III: DSC of (a) Stearic acid and (b) FNO  
Drug excipients compatibility study: 
The IR spectra of FNO and excipient Figure IV were 
compared with the standard spectrum of FNO and 
excipient. The interaction between the drug and the 
excipient often leads to identifiable changes in the IR 
profile of spectrum. IR spectra of drug excipients mixture 
showed no interaction with the FNO and prominent peaks 
of FNO were not affected.  There was neither shift and nor 
disappearance of characteristic peaks suggesting that there 
is no interaction between FNO and other excipients or no 
degradation in drug molecule. Hence drug excipients 
compatibility was established. 
 
 
Figure IV: FTIR Spectra of (a) FNO (b) Stearic acid (c) Paraffin oil (d) FNO: Stearic acid (e) FNO: Paraffin oil and (f) FNO: 
Stearic acid: Paraffin 
Preparation of Liposphere by Melt Technique:
 11, 12
 
The lipospheres contain lipid core that consists of 
physiological naturally occurring biodegradable lipids, 
thus minimizing the danger of acute and chronic toxicity. 
The lipid that constitutes the core component of the 
lipospheres is solid at room temperature, and might melt, 
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or stay solid at body temperature, depending on the 
particle design. By utilizing solid lipid as a core, several 
setbacks associated with the usage of liquid or semi-liquid 
lipid core might be reduced or avoided, i.e. inherent 
instability and irreversible drug/excipient precipitation. 
Usually, the oil, which has a maximum solubilizing 
potential for the drug under investigation, is initially 
selected with the intention of achieving the maximal drug 
loading in the lipospheres. Paraffin oil added in the 
solubilization of drug. The neutral lipids that are usually 
utilized for the hydrophobic core of the liposphere 
formulations are tricaprin, trilaurin, tristearin, stearic acid, 
ethyl stearate, and hydrogenated vegetable oil. In the 
present study stearic acid was selected as it posses polar 
carboxylic acid group, which made the matrix more 
susceptible to hydration and thereby created a hydrophilic 
pathway for water molecules to access drug. This 
decreases the resistance to diffusion of the dissolution fluid 
through the wax matrix and increases the drug dissolution. 
The lower melting point and density of stearic acid also 
reported to be contributing factor to enhancing the drug 
release from the heterogeneous wax matrix system. The 
choice of an appropriate surfactant for the liposphere 
formulations is often dictated by safety considerations. 
Emulsifiers of natural origin are preferred since they are 
considered to be safer than the synthetic surfactants. Non-
ionic surfactants are less toxic than ionic surfactants but 
they may lead to reversible changes in the permeability of 
the intestinal lumen. The usage of organic solvent was 
avoided as discolouration of drug in the capsule due to 
volatility. 
EVALUATION OF LIPOSPHERES 
Bulk Characterization: 
Angle of Repose 
As presented in the Table IV the angle of repose of the 
factorial batches of lipospheres were in the passable range 
of 33.01 to 34.69. The presence of aerosil improved the 
flow property of the lipospheres. 
Bulk Density and Tapped Density 
The bulk density as shown in the Table IV depends upon 
the particle size, shape and the cohesiveness between the 
particles. The values of bulk and tap densities of the 
factorial batches were found in the range of 0.2021to 
0.2586 and 0.3041 to 0.3865 respectively. 
 
Table IV: Micromeretics properties of factorial batches 
Formulation code Bulk Density Tapped Density Carr’s Index Angle of Repose 
F1 0.2021 0.3041 33.54 32.63 
F2 0.2109 0.3238 34.86 32.18 
F3 0.2210 0.3546 37.67 33.01 
F4 0.2347 0.3548 33.85 34..69 
F5 0.2401 0.3854 37.7 36.27 
F6 0.2504 0.3481 33.77 32.5 
F7 0.2586 0.3865 33.09 33.81 
F8 0.2216 0.3455 35.86 34.31 
F9 0.2117 0.3352 36.84 33.25 
 
Carr’s Index (CI) 
The values of Carr’s index of the factorial batches were in 
the range from 33.09 to 37.7as have been shown in the 
Table IV supporting the fact that were out of acceptable 
range with poor property of compression.  
% Yield: 
% Yield has been exhibited in the Table V. The presence 
of stearic acid showed a drastic change in % yield, %DE 
and hence in %DR. 
% Drug Entrapment: 
 13
 
% Drug entrapment  of drug entrapped within the polymer 
matrices were in the range of 70-97 % as has been shown  
in the Table V. An entrapment efficiency depends on  the 
drug solubility in the solvent system used for processing. 
Various co-solvents such as ethanol, di methyl sulfoxide 
and dimethylformamide been often used  in the 
formulation of lipospheres since they aid in  the higher 
drug  entrapment.  
 
Table V: % Yield %DE and cumulative % DR of factorial batches 
Formulation code %  Yield % Drug Entrapment %  Drug Release 
F1 38.00  80.00 ± 0.105 63.051 ± 0.061 
F2 42.81  79.75 ± 0.109 87.870 ± 0.620 
F3 47.44  77.50 ± 0.102 60.250 ± 0.058 
F4 44.22  84.08 ± 0.119 67.791 ± 0.517 
F5 46.81  97.89 ± 0.151 90.690 ± 0.032 
F6 42.14  82.12 ± 0.133 73.560 ± 0.567 
F7 45.10  81.12 ± 0.157 68.460 ± 0.319 
F8 41.76  86.92 ±0.146 79.890 ± 0.092 
F9 44.32  70.92 ± 0.120 65.670 ± 0.168 
Data represents n=3, mean± S.D. 
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Morphology: 
The surface morphology of the lipospheres prepared by 
melt technique was studied and has been depicted in 
Figure V.  The SEM showed uniformly sized spherical 
lipospheres with minimum evidence of the crystals of FNO 
suggesting presence of FNO as solid solution in the carrier. 
 
 
Figure V: SEM of lipospheres 
Differential Scanning Calorimetry (DSC) study:  
Differential Scanning Calorimetry enables the quantitative 
detection of all processes in which energy is required or 
produced (i.e. endothermic and exothermic phase 
transformations) Thermogram lipospheres have been 
depicted in Figure VI. In the case of pure FNO, a sharp 
endothermic peak was observed at 82°C, corresponding to 
the melting point of FNO. Stearic acid thermogram (bulk 
material) also displayed  an endothermic peak at 68°C 
corresponding to melting point of stearic acid. No 
endothermic peak corresponding to fusion of FNO was 
observed in the thermogram of drug loaded liposphere.  
 
 
Figure VI: DCS spectra of lipospheres 
 
In-vitro drug release study: 
The drug release from lipospheres in phosphate buffer pH 
6.8 has been shown in Figure VII. Cumulative % drug 
release from F1, F3, F4, F7 and F9 were in the range of 
60-68% within 12hours. Drug released from F6, and F8 
were73-79 % within 12 hr. Drug release from F2 and F5 
were 87-90% within 12hours. No formulation is showing 
burst release which indicates the absence of free particles 
on the surface of lipospheres which further confirmed by 
SEM study. The trail revealed that low level of stearic acid 
(25%) failed to produce liposphere with acceptable 
physical characteristic where as high level of stearic acid 
(100%) resulted in liposphere that exhibited high 
percentage of drug release. As the level of paraffin oil 
increases the particle size of liposphere increases due to 
tackiness which in turn decrease the % drug release from 
the liposphere. 
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Figure VII: Cumulative % drug release profile of factorial batches (F1-F9) 
Optimized formulation 
Evaluation of Dependent Variables and Mathematical 
Modeling: 
The values of dependent variables of liposphere 
formulations are necessary to get polynomial equations 
from Design Expert software for the respective dependent 
variable. Mathematical relationships generated using 
multiple line regression analysis (MLRA) for the studied 
response variables are expressed in Equation VII, IX. 
% Drug Entrapment (Y1):=+82.255556 + 6.74500*X (16) 
% Release within 12hr 
 (Y2): =+81.41000–8.23333*X+0.69967*Y 12.5733*Y2 (17) 
The response surface diagrams, known to facilitate an 
understanding of the contribution of the variables and their 
interactions, and their respective contour maps are shown 
for all the responses in Figure VIII, IX. In the Figure VIII 
response surface plot reveals that for 97% of % drug 
entrapment the concentration of stearic acid and paraffin 
oil should be in the range of100-400mg and 40-60mg 
respectively. Thus it reveals that concentration of stearic 
acid & concentration of paraffin oil have significant effects 
on the % drug entrapment of lipospheres. 
 
Figure VIII: A contour plot showing relationship between various levels of polymers to attain fixed values of % 
Drug entrapment 
 
Figure IX: A contour plot showing relationship between various levels of polymers to attain fixed values of % drug 
release within 12 hours 
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Figure IX reveals an improved drug release in 12hours 
with an increased concentration of stearic acid. This may 
be due to the hydrophobic nature of stearic acid that 
improves wetting of hydrophobic material by reducing 
angle of contact between dissolution medium and material 
and helps in diffusion of drug. The decline in the drug 
release with an increase in paraffin oil concentration may 
be attributed to the slower rate of diffusion medium into 
the liposphere due to an increase in thickness of polymer 
matrix. For % drug entrapment, the F and P values were 
found to be 11.92 & 0.0107 respectively, implying the 
significance of model. For % drug release within 12 hours, 
the F and P values were found to be 5.53 & 0.0480 
respectively, implying the significance of model.  Since 
the values of r2 were 0.6300 & 0.7684 for % drug 
entrapment and cumulative % drug release respectively for 
12hours, the polynomial equations fits excellently to the 
experimental data. 
Saturation Solubility: 
Table VI summarizes the experimentally determined 
saturation solubility of FNO liposphere in phosphate buffer 
with 1% SLS. The solubility of FNO (API) was found to 
be 79.56μg/ml. The liposphere with hydrophobic polymers 
and surfactants improved the drug solubility, probably due 
to the solubilization of FNO in the liposphere due to an 
adsorption of hydrophobic polymer and surfactant.  
Table VI: Saturation solubility of FNO lipospheres 
FNO 79.56µg/ml 
Physical mixture 184.31µg/ml 
Lipospheres 352.67 µg/m 
In vitro drug release of optimized batch: 
The optimized batch Q1 shown in the Figure X and also in 
Table VII similar release profile compared to factorial 
batches F5 Release shown was 89.069% in 12 hours and 
the best fit model was Korsmeyer-Peppas. Its n value was 
found to be 0.7683. FNO loaded liposphere showed the 
fastest dissolution rate, with approximately 90% of the 
drug being released within 12 hours. Addition of aerosil 
has been shown to reduce the aggregation tendencies of 
lipospheres, reduced aggregation leads to improved 
wetting and thereby increased dissolution rate. FNO 
liposphere with nonionic surfactant exhibited a faster 
dissolution rate. Once the gelatine capsule had dissolved, 
the FNO liposphere dispersed rapidly within the 
dissolution medium, in contrast to the plane FNO which 
showed some aggregation and floating of a portion of the 
drug on the surface of the dissolution medium throughout 
the experiment. 
 
Figure X: Cumulative % drug release of optimize batch Q1 
Table VII: Cumulative% drug release of optimize batch Q1  
Dependent variables Optimized formulation F1 
Experimented 
value 
Predicted 
value 
%Drug Release 89.653±0.673 89.069 
%Drug Entrapment  89.006±0.413 89.001 
 
In vivo Study of optimized batch: 
In vivo efficiency of the best found formulation of FNO 
lipospheres (Q1) was performed on healthy normal Wistar 
albino rats by measuring the lipid profile after an oral 
administration. The lipospheres were administered at a 
dose equivalent to 800μg/ kg in suspension form. As 
depicted in the Figure XI, XII, XII and Table VIII rapid 
reduction in cholesterol, triglyceride and low density 
lipoprotein levels was observed and maximum reduction of 
45.41%, 49.58%, and 45.67% was observed within 8hours 
after oral administration respectively. 
 
Table VIII: Reduction in lipid profile levels at different time intervals 
Sr. No 
Time 
(h) 
Parameters 
Cholesterol Triglyceride Low Density Lipoprotein 
Control Liposphere 
Treated 
Control Liposphere 
Treated 
Control Liposphere 
Treated 
1 0 98.45±0.10 98.45±0.49 97.21±0.96 96.52±0.78 96.82±0.07 97.87±0.09 
2 1 98.31±0.35 85.89±0.01 98.35±0.05 83.51±0.19 98.69±0.43 84.69±0.36 
3 2 97.47±0.40 72.22±0.07 96.41±0.47 72.59±0.63 98.20±0.09 75.53±0.74 
4 5 94.53±0.15 56.41±0.09 93.25±0.79 61.89±0.89 93.61±0.12 62.15±0.61 
5 8 96.63±0.23 45.41±0.41 95.61±0.61 49.58±0.06 94.59±0.60 45.67±0.34 
6 12 97.18±059 84.23±0.57 96.83±0.33 82.53±0.04 93.75±0.71 84.19±0.07 
7 24 97.47±0.05 97.91±0.39 93.52±0.49 96.28±0.09 95.45±0.57 94.21±0.91 
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Figure XI: % Reduction of cholesterol in albino rats 
 
Figure XII: Reduction of triglyceride in albino rats 
 
Figure XIII: % Reduction of low density lipoprotein 
CONCLUSION: 
The present study focused on the development of 
lipospheres of Fenofibrate by using stearic acid and 
Paraffin oil as a release retarding polymer using melt 
dispersion technique. The Invivo data supports the 
retardation of lipid profile of single dose. 
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